Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Masked, Placebo-Controlled Phase 1/2a Study of the Efficacy and Safety of Two Dosing Regimens of RVL-1201 in the Treatment of Acquired Blepharoptosis
Conditions
Interventions
RVL-1201
RVL-1201 Vehicle Placebo
Locations
1
United States
Morrow, Georgia, United States
Start Date
May 1, 2013
Primary Completion Date
January 1, 2014
Completion Date
February 1, 2014
Last Updated
November 26, 2021
NCT03812016
NCT06683651
NCT05945615
NCT05715346
NCT06292182
NCT04807855
Lead Sponsor
RVL Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions